logo

PYPD

PolyPid·NASDAQ
--
--(--)
--
--(--)

PYPD fundamentals

PolyPid (PYPD) released its earnings on Feb 11, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.41 (YoY +63.72%), missed estimates.
Revenue / YoY
0
--
EPS / YoY
-0.41
+63.72%
Report date
Feb 11, 2026
PYPD Earnings Call Summary for Q4,2025
  • Regulatory Momentum: FDA supports rolling NDA submission for D-PLEX100, with initial label targeting colorectal surgery.
  • Commercial Progress: Advanced partnership discussions with hospital-based experts; 2026 expected to finalize agreements.
  • Financial Stability: $12.9M cash on hand, with $3.7M from warrant exercises, funding operations into H2 2026.
  • Innovation Expansion: Kynatrix platform expands to systemic therapies (e.g., GLP-1), complementing D-PLEX100's localized delivery.
  • Growth Catalysts: 2026 poised for regulatory approval, commercial launch, and pipeline expansion into metabolic disease.

Earnings

EPS
Revenue

Revenue & Expenses

Key Indicators

PolyPid (PYPD) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

PolyPid (PYPD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown

Balance Sheet

PolyPid (PYPD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown

Cash Flow

PolyPid (PYPD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown

Revenue Breakdown

Where does PolyPid (PYPD) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:

Dividend

Track PolyPid (PYPD) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield